Moshe Arkin Urges Eiger BioPharmaceuticals (EIGR) to Maximize Value with Lonafarnib Focus

Key Summary: On November 14, 2023, Moshe Arkin (10%) urged the Board to prioritize Lonafarnib's potential for treating Hepatitis Delta Virus (HDV), proposing a new drug application and financing through a private offering with major shareholders. He suggested adding investor representatives to the Board to boost the stock price and aimed to collaborate …